Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results [Yahoo! Finance]
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
Aurinia: Updated Lupkynis Label Should Keep Sales Growth Momentum Going [Seeking Alpha]
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program [Yahoo! Finance]